Compare MPB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | OMER |
|---|---|---|
| Founded | 1868 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 772.8M |
| IPO Year | 1996 | 2008 |
| Metric | MPB | OMER |
|---|---|---|
| Price | $31.77 | $14.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $32.50 |
| AVG Volume (30 Days) | 110.0K | ★ 983.1K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $233.22 |
| P/E Ratio | $89.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.83 | $2.95 |
| 52 Week High | $35.22 | $17.65 |
| Indicator | MPB | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 64.28 |
| Support Level | $31.17 | $10.82 |
| Resistance Level | $31.95 | $15.32 |
| Average True Range (ATR) | 0.86 | 0.64 |
| MACD | -0.23 | -0.07 |
| Stochastic Oscillator | 13.74 | 73.59 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.